AB Science announces assay for first patient in phase 2 trial of antiviral activity of masitinib against SARS-CoV-2 (COVID-19) virus
AB SCIENCE ANNOUNCES FIRST PATIENT DOSAGE FOR PHASE 2 ANTIVIRAL ACTIVITY TRIAL OF MASITINIB AGAINST SARS-CoV-2 (COVID-19[female[feminine) VIRUS
Paris, 29 November, 2021, 8.45afternoon HEC
AB Science SA (Euronext – FR0010557264 – AB) announced today that the first patient has received a dose in the Phase 2 trial evaluating the antiviral activity of masitinib in patients with a confirmed diagnosis of COVID-19.
The study plans to enroll 78 patients, either non-hospitalized patients with mild illness or hospitalized patients without non-invasive ventilation. The main efficacy goal will be to demonstrate that masitinib can reduce the viral load of SARS-CoV-2 (the virus responsible for COVID-19) faster than a placebo control group, which will receive the best supportive care. The AB21002 study has so far been authorized in Russia and South Africa where COVID-19 is particularly active.
Alain Moussy, co-founder and CEO of AB Science said: âThe New The Omicron variant reminds us that the SARS-CoV-2 virus evolves rapidly with the selection and accumulation of mutations, mainly in the Spike protein, and this these mutations can lead to increased transmissibility virus and potentialI escape from some vaccines. Obviously, There are a continued need for effective antiviral treatments that are immune to these variants.“
Professor Olivier Hermine, Chairman of the Scientific Committee of AB Science and member of the AcadÃ©mie des Sciences in France declared: âMasitinib a unique Properties among potential treatment options for patients with COVID-19. It has antiviral activity against the original virus and also against the alpha, beta and delta variants, like is to be waited with a anti-protease drug. It should also be active against Omicron vAriant because his activity is not dependent on peak protein. In addition, masitinib is an anti-inflammatory through its ability to block the immune response induced by macrophages and mast cells. Antiviral treatments should be taken within the first few days of infection to maximize their effectiveness; However, masitinib can be effective even if taken later because it’s not alone an antiviral medication. This goods could be of critical importance for patients with co-morbidities. Also, long–effective termvsnext to COVID-19 imitate mast cell activation syndrome, especially regarding neurological symptoms, and masitinib maybe also represent an option for to treat long–term effects of COVID-19 (long COVID).“
Alain Moussy further indicated: âWe are committed to continue clinical development of masitinib in COVID-19 because this pandemic is clearly not finished Again. What’s more, masitinib seems to be a unique drug in the anti-COVID arsenal, having potential therapeutic activity generally of his steps to the merit of his double antiviral/anti-inflammatory action mechanism.“
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, cells important for immunity, by inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of pathologies in oncology, in inflammatory diseases and in certain diseases of the central nervous system. In oncology, because of its immunotherapeutic effect, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and therefore inhibiting the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases and the degeneration of these diseases. .
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKI), a class of targeted proteins whose action is essential in signaling pathways within cells. . Our programs only target diseases with high unmet medical needs, often fatal with short-term survival or rare or refractory to the previous line of treatment.
AB Science has developed an exclusive portfolio of molecules and the Company’s flagship compound, masitinib, has already been registered in veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and is listed on Euronext Paris (ticker: AB).
Further information is available on the AB Science website:
Forward-looking statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on plans, objectives, intentions and expectations regarding financial results, events, operations, future services, development. of products and their potential or future performance.
These forward-looking statements can often be identified by the words âexpectâ, âanticipateâ, âbelieveâ, âintendâ, âestimateâ or âplanâ and other similar terms. Although AB Science believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties which are difficult to predict and generally beyond the control of AB Science and which may imply that the results and actual events differ materially from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include uncertainties related to the development of the Company’s products which may not be successful or to the marketing authorizations granted by the competent authorities or, more generally, any factor that may affect the marketing capacity of the products developed by the Company. AB Science, as well as those developed or identified in public documents published by AB Science. AB Science declines any obligation or commitment to update forward-looking information and statements, subject to applicable regulations, in particular Articles 223-1 and following. of the AMF general regulations.
For more information, please contact:
Financial Communication & Press Relations
Media Relations – United States
+1 212 223 0561
Press relations – France
+33 (0) 1 44 71 00 15